timbetasin topical (RGN-137) / RegeneRx  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
timbetasin topical (RGN-137) / RegeneRx
NCT00382174: Study of Thymosin Beta 4 in Patients With Pressure Ulcers

Completed
2
72
US
Placebo, Thymosin Beta 4
RegeneRx Biopharmaceuticals, Inc.
Pressure Ulcers
12/08
12/08
SSVS, NCT00832091 / 2005-004500-37: Study of Thymosin Beta 4 in Patients With Venous Stasis Ulcers

Completed
2
72
Europe
Thymosin Beta 4, Tβ4, RGN-137 (topical gel), Placebo
RegeneRx Biopharmaceuticals, Inc., sigma-tau i.f.r. S.p.A.
Venous Stasis Ulcers
01/09
01/09
NCT00311766: A Phase 2 Study on Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa

Terminated
2
30
US
Thymosin Beta 4, Placebo
RegeneRx Biopharmaceuticals, Inc.
Epidermolysis Bullosa
07/10
11/12
NCT03578029: Evaluation of the Safety and Efficacy Study of RGN-137 Topical Gel for Junctional and Dystrophic Epidermolysis Bullosa

Terminated
2
4
US
RGN-137, Dermal Topical Gel, Placebo, Vehicle Control
Lenus Therapeutics, LLC
Junctional Epidermolysis Bullosa, Dystrophic Epidermolysis Bullosa
09/21
11/21

Download Options